The Medical Minute: Thyroid cancer on the rise

September 21, 2012
The Medical Minute: Thyroid cancer on the rise
Leah Cream, a Penn State Hershey oncologist, talks about how she got the upper hand on thyroid cancer.

September is Thyroid Cancer Awareness Month. With cases on the rise locally, nationally and globally, Dr. David Goldenberg, director of Head and Neck Surgery at Penn State Hershey Medical Center, hopes people will become more mindful of the disease.

"In 1980 it was the 20th most common cancer in the United States. Now it's the eighth," Goldenberg said. "It is the fastest growing new cancer amongst women. What we don't know and don't understand is why."

The is a butterfly shaped gland located on the front of the neck that produces hormones that help the body control metabolism. The prognosis overall for thyroid cancer is very good: Most patients go on and lead a full, healthy life with thyroid replacement therapy, Goldenberg said. While anaplastic and equally rare medullary thyroid cancers both carry a , follicular and papillary thyroid cancers are much more easily treated. is the most common type, encompassing 80 to 85 percent of all thyroid cancer.

According to Goldenberg, there are no signs or symptoms until "very, very late in the game." The vast majority of thyroid cancers are found when a physician is doing a physical exam on a patient or when a patient is undergoing testing for a completely different reason. Nodules (growths or ) are found on the thyroid, and that prompts further testing.

" are extremely common, and only one out of 20 of these nodules will actually be a cancerous nodule," he said.

While there are no recommendations for routine screenings of the general population, Goldenberg said people exposed to radiation at a very early age or with a history of thyroid cancer are more at risk.

"Those patients certainly should have at the very least a and perhaps an ultrasound as well," he said. "And they probably should have a more thorough investigation."

Treatment for thyroid cancer is typically surgical in the form of a thyroidectomy, or removal of the thyroid. In addition, patients are given radioactive iodine in the form of a liquid or a pill to complete treatment.

It is not uncommon for thyroid cancer survivors to have a recurrence. Up to 25 percent of patients may have a recurrence of papillary thyroid cancer after initial treatment.

"The recurrence typically happens in the neck and fortunately does not negatively impact the patient's prognosis. In short, even if the patient has a recurrence of papillary thyroid cancer, chances are they'll do just fine," Goldenberg said.

Papillary thyroid cancer sometimes spreads to the lymph nodes in the neck. Those patients undergo a neck dissection, which is the removal of a chain of lymph nodes along the jugular vein in the neck.

To pinpoint what's caused the increase in thyroid cancer cases, researchers are now looking at risk factors including radon, obesity and diabetes as part of their ongoing studies. Looking at the effects of certain types of chemotherapy to treat and possibly cure anaplastic thyroid cancer, for which there currently are no effective treatments, is also part of their investigation.

Even with the majority of positive outcomes, Goldenberg urges his peers in the oncology community as well as government agencies that allot funding to research to recognize thyroid cancer and its increasing number of cases.

" is on the rise," he said. "The rates are soaring, and the reasons are not really very clear to us. So there needs to be more of an interest and more funding because we'll only be hearing more about this type of cancer as time goes on."

Explore further: Removal of lymph nodes during surgery for thyroid cancer may be beneficial

Related Stories

Removal of lymph nodes during surgery for thyroid cancer may be beneficial

December 20, 2011
Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women. A new study indicates that routinely removing lymph nodes in the neck in these cancer patients may help prevent ...

BRAF addiction of thyroid cancers makes them therapeutically vulnerable

November 21, 2011
Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly ...

Have no fear: Most cases of thyroid cancer do not affect survival

June 11, 2012
Research presented at the Society of Nuclear Medicine's 59th Annual Meeting reveals that patients with differentiated thyroid cancer live as long as people in perfect health, unless they are in the minority and have reached ...

African-Americans with thyroid cancer fare worse than whites

June 21, 2011
African-Americans have fewer incidences of thyroid cancer but have a more advanced form of the disease once they receive a diagnosis -- and are more likely to die from it, according to a new study.

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.